Abstract Purpose: We previously identified three genes, HOXB13, IL17BR, and CHDH, that strongly predict clinical outcome in estrogen receptor (ER)^positive breast cancer patients receiving tamoxifen monotherapy. The biological mechanisms linking these genes to estrogen signaling and tamoxifen response in breast cancer remain to be determined. Experimental Design: In a consecutive series of 148 ER-positive and ER-negative breast cancers, HOXB13, IL17BR, and CHDH gene expression was measured by quantitative real-time PCR and correlated with ER, PR, and HER2 expression. The role of estrogen and ER in the regulation of these three genes was assessed in several ER-positive and ER-negative breast cancer cell lines. Results: In primary breast tumors, HOXB13 expression correlated negatively, and IL17BR and CHDH expression correlated positively, with ER status, and all three genes exhibited an ER-dependent correlation pattern with HER2 status that differs from PR and PS2, two canonical estrogen-regulated genes. Results using breast cancer cell lines show that these genes are regulated by estradiol in an ER-dependent manner, and that this regulation is abrogated by tamoxifen. Conclusions: HOXB13, IL17BR, and CHDH are estrogen-regulated genes, but their pattern of correlation with known positive (ER, PR) and negative (HER2) predictors of tamoxifen response differs from canonical ER signature genes. These results provide a biological rationale for the prognostic utility of these three genes in early-stage ER-positive breast cancer and for their potential to predict anti-estrogen resistance.
overexpressed in patients with favorable outcome, whereas the homeobox gene HOXB13 was overexpressed in patients who experienced a more aggressive clinical course (i.e., tamoxifen resistance).
Since these initial observations, three additional studies have further assessed the prognostic and predictive utility of the HOXB13:IL17BR expression ratio in women with breast cancer (11 -13) . Goetz et al. (11) analyzed the two-gene expression index in a cohort of 206 postmenopausal women with ERpositive breast cancer from a prospective randomized adjuvant tamoxifen trial and revealed that a high HOXB13:IL17BR index was predictive of early relapse and death in node-negative but not in node-positive patients. In a cohort of 852 breast cancer patients, the two-gene index was further shown to be a strong independent prognostic factor for ER-positive node-negative breast cancer patients irrespective of tamoxifen therapy (13) . Independently, Jansen et al. (14) have recently shown in a cohort of 812 ER-positive breast cancer patients that high HOXB13:IL17BR index expression levels were associated with both tumor aggressiveness and tamoxifen therapy failure.
To begin to understand the biological context underlying the prognostic and predictive potential of HOXB13, IL17BR, and CHDH, we sought to determine whether these genes are regulated by estrogen signaling in breast cancer. In a population-based, consecutive series of women diagnosed with ER-positive and ER-negative breast cancer, we show that HOXB13, IL17BR, and CHDH expression correlates with ER and HER2 status. Furthermore, we show that gene expression of HOXB13, IL17BR, and CHDH is regulated by estrogen in an ER-dependent manner, which, in turn, is abrogated by tamoxifen. The estrogen-regulated pattern of HOXB13, IL17BR, and CHDH expression differs from canonical ER signature genes, suggesting that these genes may serve as a biomarker for dysfunctional ER signaling.
Materials and Methods
Patients. The Massachusetts General Hospital institutional review board approved this study in accordance to NIH guidelines. To avoid bias, formalin-fixed, paraffin-embedded (FFPE) tumor samples from 75 consecutive ER-positive and 73 consecutive ER-negative invasive breast carcinomas diagnosed at the Massachusetts General Hospital (Boston, MA) between 2005 and 2006 were prospectively collected and processed for RNA extraction and real-time quantitative PCR. Receptor status had been determined by immunohistochemistry using the BenchMark XT automated system (Ventana Medical Systems Inc.). Only cases with more than 10% positivity of tumor cells were considered as ER positive. HER2 amplification was determined by fluorescence in situ hybridization using the PathVysion HER-2 DNA probe kit (Vysis). For each case, the ratio of z2 HER2 to CEP 17 signals in at least 60 interphase tumor cell nuclei was considered as amplification of HER2. Clinicopathologic characteristics are described in Table 1 .
RNA isolation from FFPE tumor samples and real-time quantitative PCR. Total RNA was isolated from two to three 5-Am tissue sections for each sample using Optimum FFPE RNA isolation kit from Ambion Diagnostics according to the manufacturer's instructions and reversetranscribed into cDNA using gene-specific reverse priming using Powerscript Reverse Transcriptase (Clontech Laboratories) Reagent System. TaqMan primers and probes were designed using Primer Express (Applied Biosystems) for 10 genes ( Table 2) . The three reference genes (ACTB, HMBS , and UBC) were selected by assessing 10 commonly used housekeeping genes in an independent breast cancer cohort, as described previously (13) . Gene expression was quantitated by TaqMan reverse transcription-PCR (RT-PCR) in triplicate in 96-well plate using an ABI 7900HT (Applied Biosystems) as described Cell culture and reagents. The T47D cell line was obtained from the American Type Culture Collection and maintained in DMEM supplemented with 10% FCS (DMEM-FCS). The MDA-MB-436, -453, and -468 human breast cancer cells were a generous gift from Daphne Bell (Massachusetts General Hospital, Boston, MA). MCF-7 cells (BUS stock) were maintained as previously described (15, 16) . MDA-MB-231-neo and MDA-MB-231-ER8 cells were generously provided by Robert Weinberg (Massachusetts Institute of Technology, Cambridge, MA) and maintained as described (17) . Charcoal/dextran-treated fetal bovine serum (cFBS) and fetal bovine serum (FBS) were obtained from Hyclone Laboratories, Inc. Tamoxifen and 17h-estradiol were obtained from Sigma Chemical Co.
Data analysis. All statistical analysis was done in the R statistical software. Association of continuous variables with binary factors (e.g., ER/HER2 status) was tested using nonparametric Wilcoxon twosample test. Pair-wise gene-gene correlations were examined using the Pearson correlation coefficients. Relative gene expression levels in the cell line studies were compared between two conditions using the Student's t test with unequal variance. All P values are two-sided, and P values <0.05 were considered significant.
Results
Correlation of HOXB13, IL17BR, and CHDH expression with the estrogen and progesterone receptor. Using a populationbased cohort of 75 consecutive ER-positive and 73 ER-negative invasive breast cancers, we investigated the correlation of HOXB13, IL17BR, and CHDH gene expression with the estrogen and progesterone receptors, two well-known positive biomarkers of tamoxifen response. First, we correlated the mRNA levels of HOXB13, IL17BR, and CHDH with ER status as determined by immunohistochemistry (Fig. 1) . The relative (Fig. 1A) , whereas the relative expression of IL17BR and CHDH was significantly higher in ER-positive tumors as compared with ER-negative tumors (Fig. 1B and C) . Using a Gaussian model -based clustering technique, HOXB13 mRNA levels were found to be bimodal, with 67% of ER-negative tumors and 50% of ERpositive tumors expressing HOXB13 (Fig. 1D) . Next, we correlated the expression of HOXB13, IL17BR, and CHDH with ER mRNA levels as well as two other well-characterized estrogen-regulated genes, PR and pS2. Clustering of all pairwise correlation coefficients among these genes indicated that HOXB13 correlated negatively with ER, whereas IL17BR and CHDH correlated positively with each other and with ER ( Fig. 2 and Table 3 ). As expected, the expression of PR and PS2 (Trefoil factor 1, TFF1), two canonical ER signature genes, correlated most strongly with ER. However, the positive correlation of IL17BR and CHDH with ER was less than that of PR and pS2 (Table 3) .
Correlation of HOXB13, IL17BR, and CHDH expression with HER2. Using the same cohort described above, we next investigated the correlation of HOXB13, IL17BR, and CHDH mRNA expression with HER2 status, a known negative predictor of tamoxifen response. Notably, these three genes exhibited an ER-dependent correlation pattern with HER2 status (Fig. 3) . More specifically, HOXB13 expression positively correlated with HER2 status in ER-positive but not in ERnegative tumors, and IL17BR and CHDH negatively correlated with HER2 status more strongly in ER-positive tumors than in ER-negative tumors. Interestingly, this ER-dependent correlative pattern for these genes with HER2 is distinct from that for PR and PS2 in that neither of these latter genes showed significant correlation with HER2 status in ER-positive tumors (Fig. 3) .
Expression of HOXB13, IL17BR, and CHDH is regulated by estradiol. The observation that IL17BR and CHDH expression directly correlates and HOXB13 expression inversely correlates with ER expression raises the possibility that these three genes are targets of estrogen signaling. To address this issue, we exposed several ER-positive and ER-negative breast cancer cell lines to estradiol (E2) and measured transcript levels of all three genes by real-time quantitative-PCR (QRT-PCR). As expected, E2 stimulation resulted in elevated expression of PS2 in the ER-positive MCF7 and T47D cells, but in none of the three ERnegative cell lines (Fig. 4A) . HOXB13 expression was significantly reduced, and IL17BR and CHDH expression was significantly increased by E2 in the ER-positive MCF7 and T47D cell lines, but not in the ER-negative cell lines (MDA-MB-436, MDA-MB468, and MDA-MB-453; Fig. 4A ). Therefore, these data suggest that HOXB13, IL17BR, and CHDH are estrogen-responsive genes, consistent with their respective correlations with ER status in primary breast tumors described above. Furthermore, this estrogen response is not seen in ERnegative cells, suggesting a requirement for the ER.
To further test whether the E2 response of HOXB13, IL17BR, and CHDH requires functional ER, we evaluated the ability of ectopically expressed ER to modulate HOXB13, IL17BR, and CHDH expression. We measured transcript levels of these three genes in ER-negative MDA-MB-231 cells engineered to stably express a functional ER (17, 18) . As compared with the parental MDA-MB-231 cell line, the ER-expressing MDA-MB-231 cells (MDA-MB-ER8) in the presence of E2 show dramatically elevated expression of IL17BR and CHDH and a near-complete suppression of HOXB13 expression (Fig. 4B) . These results suggest that E2 regulation of HOXB13, IL17BR, and CHDH is mediated through the ER.
Because HOXB13, IL17BR , and CHDH were initially discovered as prognostic biomarkers in ER-positive patients treated with tamoxifen monotherapy (4), we next determined whether the estrogen response of these genes could be modulated by tamoxifen, a partial anti-estrogen. We stimulated MCF7 cells with two doses (0.1 and 1 nmol/L) of E2 in the presence or absence of 5 nmol/L tamoxifen. As a control, E2 resulted in 15-fold increase in PS2 expression, which was blocked by tamoxifen (Fig. 5) . Notably, the enhancement of IL17BR and CHDH expression and the suppression of HOXB13 expression by E2 were abrogated by tamoxifen (Fig. 5) .
Discussion
Estrogen plays an important role in breast cancer pathogenesis, and selective interference of the estrogen/ER-mediated signaling cascade is the most effective means of treating ER-positive breast cancer patients. High-throughput gene expression technologies have revealed a robust gene expression signature that readily distinguishes ER-positive tumors from ER-negative tumors (6, 19) . Comparative analysis of ER-positive breast tumor gene expression profiles with those generated from E2-stimulated breast cancer cell lines has shown a remarkable overlap of genes (20) . However, despite the identification of such ER gene expression signatures, it remains to be determined which gene or subset of genes regulated by estrogen is critical for breast tumorigenesis.
Previously, through genome-wide expression profiling, we identified a simple gene expression pattern that sub-stratifies ER-positive breast cancer patients into good and poor prognosis categories (4). More specifically, we have shown that a distinct breast cancer gene expression pattern characterized by higher levels of HOXB13 and lower levels IL17BR and CHDH gene expression predicts for distant tumor recurrence in tamoxifentreated patients with ER-positive breast cancer (4, 11, 13) . More recently, data generated by Jansen et al. (12, 14) suggest that HOXB13 and IL17BR expression is predictive of response to first-line tamoxifen monotherapy in ER-positive breast cancer patients with metastatic disease.
To begin to understand the biological mechanisms underlying their prognostic and predictive potential, we investigated whether estrogen signaling regulates HOXB13, IL17BR, and CHDH expression. Our results provide two lines of evidence indicating that these genes are regulated by estrogen. First, in a population-based, prospectively collected, consecutive series of ER-positive and ER-negative breast tumors, HOXB13 expression correlated negatively, and IL17BR and CHDH expression correlated positively, with ER status. Second, using a panel of ER-positive and ER-negative breast cancer cell lines, we showed that all three genes are estrogen responsive in an ER-dependent manner. Although these experiments do not formally establish that these genes are direct targets of the ER, this possibility is supported by results from a recent genome-wide location analysis of ER binding sites by chromatin immunoprecipitation combined with microarrays (ChIP-on-chip) in MCF7 cells upon E2 stimulation (21) . In this published ChIP-on-chip database, an ER binding site exists within the second intron (2.4 kb from the transcriptional start site) of IL17BR (21) . Due to the head-tohead genomic arrangement of CHDH and IL17BR, this same ER binding site is also just 2.8 kb upstream of CHDH, likely explaining their co-regulation by ER. In addition, this database reveals an ER-binding site that maps 76 kb upstream of the HOXB13 transcriptional start site; this long distance does not rule out its functional relevance to HOXB13 because long-range, non -proximal-promoter regulation may be important in many ER-regulated genes (21) . The functional relevance of these ER binding sites needs direct experimentation in future studies.
The bimodal expression of HOXB13 in breast cancer is notable. The promoter region and the first exon of HOXB13 contain a CpG island, and it has been shown to be hypermethylated in renal cell carcinoma as a mechanism of shutting down its expression (22) . Perhaps the bimodal expression pattern of HOXB13 in breast cancer reflects this epigenetic regulation, where promoter methylation status serves as an onoff switch for transcription.
Furthermore, our findings suggest that HOXB13, IL17BR, and CHDH are regulated by ER in a manner different from other well-known ER-regulated genes such as PR and pS2 based on the following observations. First, HOXB13 belongs to a class of genes negatively regulated by ER, likely through a different mechanism than gene activation (21) . Secondly, although IL17BR and CHDH are both positively correlated with ER expression, their extent of correlation is less than that for PR and pS2. Thirdly, all three genes showed an ER-dependent correlation pattern with HER2 status not seen with PR and pS2. Previously, the HOXB13:IL17BR index was found to be higher in HER2-positive tumors than that in HER2-negative tumors (13) . The relationship of these three E2-regulated genes to HER2 is notable because recent data from preclinical models indicate that crosstalk between the HER2 and ER signaling pathways directly contributes to the development of tamoxifen resistance (23, 24) .
Taken together, our current results suggest a biological framework to understand the proposed HOXB13:IL17BR index as a novel prognostic factor in early-stage ER-positive breast cancer patients and its potential for predicting tamoxifen resistance. Because ER functions to suppress HOXB13 and augment IL17BR expression, either directly or indirectly, hormone-responsive tumors will have a low HOXB13:IL17BR index. When estrogen signaling is impaired by either loss of ER (25, 26) , aberrant expression of certain cofactors (27) , or by HER2 signaling (24) , suppression of HOXB13 and induction of IL17BR expression is lost, resulting in a high HOXB13:IL17BR index. Therefore, the HOXB13:IL17BR index may serve as a biomarker for dysregulation of gene expression by ER and, thus, for tamoxifen resistance. Moreover, due to their distinctive patterns of correlation with ER and HER2 as noted above, HOXB13 and IL17BR may serve to report a subset of ER signaling targets different from canonical ER signature genes such as ER, PR, and pS2, thus providing distinct prognostic or predictive information. Intriguingly, a possible interplay between growth factor and estrogen signaling in the regulation of HOXB13 may be particularly relevant because we have observed synergistic action of epidermal growth factor and ectopic HOXB13 overexpression in stimulating MCF10A cell motility and invasion (4) . This interrelationship between HOXB13/IL17BR, ER, and HER2 may also be important in the context of tamoxifen resistance because a high HOX-B13:IL17BR index may indicate impaired ER signaling and increased growth factor signaling, both known to predict tamoxifen resistance (28, 29) .
In summary, HOXB13, IL17BR, and CHDH are estrogenregulated genes, and their prognostic utility is likely to reflect their complex regulation through both ER-and HER2-dependent pathways. Future work will be directed toward elucidating the pathways and cofactors used by ER to regulate these genes, understanding the functional interrelationship of these genes to the HER2 signaling pathway, and determining whether aberrant expression of these genes contributes directly to the clinical behavior of breast cancer.
